Join
Live feed
·
PRReleasevia Quantisnow
Q32 Bio Inc. logo

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

ByQuantisnow·Wall Street's wire, on your screen.
QTTB· Q32 Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QTTB (Q32 Bio Inc.) and more on Quantisnow.